Last reviewed · How we verify
SJP-0035 0.001%
SJP-0035 is a topical ophthalmic solution used to treat dry eye disease.
SJP-0035 is a topical ophthalmic solution used to treat dry eye disease. Used for Dry eye disease.
At a glance
| Generic name | SJP-0035 0.001% |
|---|---|
| Sponsor | Senju Pharmaceutical Co., Ltd. |
| Drug class | Topical ophthalmic solution |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
It works by increasing tear production in the eyes, providing relief from dryness and discomfort associated with dry eye disease.
Approved indications
- Dry eye disease
Common side effects
- Eye irritation
Key clinical trials
- Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders (PHASE2)
- A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SJP-0035 0.001% CI brief — competitive landscape report
- SJP-0035 0.001% updates RSS · CI watch RSS
- Senju Pharmaceutical Co., Ltd. portfolio CI